HK1079531A1 - 寡核苷酸綴合物 - Google Patents

寡核苷酸綴合物

Info

Publication number
HK1079531A1
HK1079531A1 HK05111412.2A HK05111412A HK1079531A1 HK 1079531 A1 HK1079531 A1 HK 1079531A1 HK 05111412 A HK05111412 A HK 05111412A HK 1079531 A1 HK1079531 A1 HK 1079531A1
Authority
HK
Hong Kong
Prior art keywords
oligonucleotide conjugates
conjugates
oligonucleotide
Prior art date
Application number
HK05111412.2A
Other languages
English (en)
Inventor
Sergei Gryaznov
Krisztina Pongracz
Richard L Tolman
Gregg B Morin
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of HK1079531A1 publication Critical patent/HK1079531A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HK05111412.2A 2002-09-25 2005-12-12 寡核苷酸綴合物 HK1079531A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/255,535 US7563618B2 (en) 2001-03-23 2002-09-25 Oligonucleotide conjugates
PCT/US2003/029730 WO2004029277A2 (en) 2002-09-25 2003-09-23 Oligonucleotide conjugates

Publications (1)

Publication Number Publication Date
HK1079531A1 true HK1079531A1 (zh) 2006-04-07

Family

ID=32041751

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111412.2A HK1079531A1 (zh) 2002-09-25 2005-12-12 寡核苷酸綴合物

Country Status (7)

Country Link
US (4) US7563618B2 (zh)
EP (1) EP1543021B1 (zh)
JP (1) JP4624104B2 (zh)
AU (1) AU2003278857A1 (zh)
CA (1) CA2499082C (zh)
HK (1) HK1079531A1 (zh)
WO (1) WO2004029277A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
PL3342425T3 (pl) * 2003-09-09 2020-06-15 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
DK2342360T3 (en) 2008-10-17 2016-04-11 Geron Corp Method for identification of sensitivity of a patient to telomerase inhibition therapy
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
SG10201909816PA (en) 2015-04-23 2019-11-28 Geron Corp Methods of polynucleotide preparation using multivalent cation salt compositions
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
BR112019004911A2 (pt) * 2016-09-14 2019-06-25 Janssen Biopharma Inc oligonucleotídeos modificados e métodos de uso
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965349A (en) * 1987-12-24 1990-10-23 Applied Biosystems, Inc. Method of synthesizing oligonucleotides labeled with ammonia-labile groups on solid phase supports
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5700636A (en) * 1990-10-19 1997-12-23 Becton Dickinson And Company Methods for selectively detecting microorganisms associated with vaginal infections in complex biological samples
YU187991A (sh) * 1990-12-11 1994-09-09 Hoechst Aktiengesellschaft 3-(2)-amino-ali tiol-modifikovani, s fluorescentnom bojom vezani nukleozidi, nukleotidi i oligonukleotidi, postupak za njihovo dobijanje i njihova upotreba
US5352803A (en) * 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5583016A (en) * 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) * 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
WO1997002279A1 (en) 1995-07-06 1997-01-23 Ctrc Research Foundation Methods and compositions for modulation and inhibition of telomerase
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en) * 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6087493A (en) 1997-02-05 2000-07-11 Regents Of The University Of Texas System Porphyrin compounds as telomerase inhibitors
US6468983B2 (en) 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
US20010039263A1 (en) * 1997-05-02 2001-11-08 Max-Delbruck-Centrum Fur Molekulare Medizin Chimeric oligonucleotides and the use thereof
DE19720151A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Chimäre Oligonucleotide und ihre Verwendung
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP0978561A1 (en) 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
US6425604B1 (en) 1999-02-23 2002-07-30 Recreational Technologies International, Llc Vehicle leveling assembly
WO2001018015A1 (en) 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
GB0014861D0 (en) 2000-06-16 2000-08-09 Pharmacia & Upjohn Spa Novel telomerase inhibitors
FR2812634B1 (fr) * 2000-08-02 2002-11-08 Inst Nat Sante Rech Med Utilisation de composes aromatiques polycycliques pour fabriquer des medicaments capables d'inhiber la telomerase
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
WO2002076397A2 (en) 2001-03-23 2002-10-03 Geron Corporation Telomerase inhibitors and methods of their use
JP4854913B2 (ja) 2001-03-23 2012-01-18 ジェロン・コーポレーション オリゴヌクレオチド結合体
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2003037909A1 (en) * 2001-10-29 2003-05-08 Mcgill University Acyclic linker-containing oligonucleotides and uses thereof

Also Published As

Publication number Publication date
US20100016416A1 (en) 2010-01-21
AU2003278857A8 (en) 2004-04-19
CA2499082A1 (en) 2004-04-08
WO2004029277A2 (en) 2004-04-08
US8440635B2 (en) 2013-05-14
AU2003278857A1 (en) 2004-04-19
EP1543021A4 (en) 2010-09-22
US20030138814A1 (en) 2003-07-24
EP1543021B1 (en) 2014-07-30
JP4624104B2 (ja) 2011-02-02
US20150374841A1 (en) 2015-12-31
CA2499082C (en) 2014-11-25
US9072790B2 (en) 2015-07-07
US7563618B2 (en) 2009-07-21
EP1543021A2 (en) 2005-06-22
JP2006507812A (ja) 2006-03-09
US20130253042A1 (en) 2013-09-26
US9572891B2 (en) 2017-02-21
WO2004029277A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
HK1079531A1 (zh) 寡核苷酸綴合物
AU2003276494A8 (en) Functional sites
AU2003249738A8 (en) Ostoscope
EP1466407A4 (en) MODULATOR / AMP
TWI319767B (en) Dendrimer
AU2003252028A8 (en) Heterodiamondoids
GB0209896D0 (en) Conjugate
EP1482957A4 (en) ANTIBIOTIC CONJUGATES
AU2003279495A8 (en) Alert-modeling
GB0119665D0 (en) Conjugates
HK1065063A1 (en) Oligonucleotide conjugates
PL373322A1 (en) Imidazolinylmethyl aralkylsulfonamides
AU2003264900A8 (en) Cast-cutter
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
GB0221778D0 (en) Conjugate
AU2003262681A8 (en) Hemo-aide
AU2003292197A8 (en) Lna-cpg conjugates
AU2002341221A8 (en) Honey-brandy
AU2003253735A8 (en) Vacuolins
GB0217672D0 (en) Powerdrive
GB2390533B (en) Undergarment
GB0224663D0 (en) DNAzyme
GB0203608D0 (en) Improved undergarment
GB0215011D0 (en) Easy squeezy
IL163551A0 (en) Antibiotic conjugates

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230922